Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.77), $0.49 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $346.29 million versus the consensus estimate of $436.08 million.

GUIDANCE:

Alnylam Pharma sees FY2024 revenue of $1400-1500 million, versus the consensus of $1770 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.